British journal of clinical pharmacology
-
Br J Clin Pharmacol · Apr 2013
Randomized Controlled TrialExenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QTc ) at therapeutic concentrations. This randomized, placebo- and positive-controlled, crossover, thorough QT study evaluated the effects of therapeutic and supratherapeutic exenatide concentrations on QTc . ⋯ These results demonstrated that exenatide, at supratherapeutic concentrations, does not prolong QTc and provide an example of methodology for QT assessment of drugs with an inherent heart rate effect.
-
Br J Clin Pharmacol · Apr 2013
Statins and risk of treated incident diabetes in a primary care population.
(i) To examine the incidence of new onset treated diabetes in patients treated with different types of statins and (ii) the relationship between the duration and dose of statins and the subsequent development of new onset treated diabetes. ⋯ An increased risk of new onset treated diabetes was found in those treated with statins showing significant duration and dose effect. Further study is required to confirm this association.